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Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease 
afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure 
to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation 
improves respiratory symptoms and lung function and reduces mortality among patients with 
COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular 
disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions 
incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor 
partial agonist, is the newest and most effective drug currently available to promote smoking 
cessation. In conjunction with behavioral interventions and clinical monitoring for potential side 
effects, varenicline offers great hope for reducing smoking-attributable death and disability.
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Epidemiology of COPD
Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease. 
In the United States alone, the disease is responsible for US$42.6 billion in annual 
expenditures.1 According to the World Health Organization (WHO), 210 million 
people around the world have COPD, with approximately 40% of those individuals 
having moderate to severe disease. Each year, 3 million people die from COPD 
making it responsible for nearly 5% of all global deaths. By 2030, COPD is predicted 
to become the third leading cause of deaths worldwide.2 In low income countries, 
indoor air pollution from cooking and heating fuels is the leading cause of COPD. 
Among middle and high income countries, cigarette smoking is the most important 
risk factor.2–5
Observational data from a number of large studies provides a clear picture 
of the impact of cigarette smoking on COPD incidence. A large Dutch cohort of 
40 to 65 year-old cigarette smokers observed a 8.3% 5-year incidence for moderate 
COPD.6 A large Swedish cohort study among middle-aged and elderly patients with 
respiratory symptoms estimated a 10-year incidence of 13.5% for the development 
of COPD.7 Another study found that one-half of all continuing smokers developed 
COPD by age 77.8
COPD management
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop 
summary provides guidelines for the diagnosis of COPD (FEV1/FVC  70%) International Journal of COPD 2009:4 422
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and for classification of patients by disease progression 
(eg, 50%  FEV1  80% of predicted defines moderate 
COPD).4 The 2008 GOLD Workshop summary defines 
four stages of COPD ranging from mild (Stage I) to very 
severe (Stage IV).4 Current standard of care for manage-
ment of patients with COPD is based upon stage of disease 
and follows the recommendations of the GOLD Workshop 
(Table 1). Of all the currently available treatment options for 
COPD, smoking cessation has the most profound impact on 
the course and prognosis of this disease.
Smoking cessation 
for the management of COPD
Smoking cessation in subjects with mild to moderate COPD 
significantly slows disease progression. Smoking cessation is 
associated with an attenuation of the decline in FEV1 and a 
decrease in all-cause and COPD-related mortality.9 The largest 
randomized clinical trial evaluating the long-term impact of 
smoking cessation on COPD was the Lung Health Study 
(LHS). In this study,10 5887 smokers with mild to moderate 
COPD were randomized to receive: 1) a smoking intervention 
and bronchodilator; 2) a smoking intervention and placebo; or 
3) no intervention (“usual care”) over 5 years. The smoking 
intervention included an emphatic physician recommendation 
to quit, group meetings focused on behavior modification, 
and nicotine gum. After quitting, former smokers participated 
in a relapse prevention program focused on coping skills. 
Over the 11 years of follow-up with 4517 of the original 
LHS participants, decline in lung function among those 
who continued to smoke was twice that of those who had 
quit. Specifically, FEV1 in men who continued to smoke 
declined by 66.1 mL/year compared to 30.2 mL/year for men 
who achieved smoking abstinence. Likewise, the decline 
in FEV1 among women was 54.2 mL/year for smokers and 
21.5 mL/year for those who achieved smoking abstinence.11 
Respiratory symptoms such as dyspnea, wheezing, chronic 
Table 1 Summary of pharmacotherapeutic interventions for the management of COPD
Intervention  Examples  Used in  
stages
Place in therapy  Clinical  
benefits
Physiological 
benefits
Mortality 
benefit
Short-acting β-agonists Albuterol
Levalbuterol
I–Iv Monotherapy or in combination with 
short-acting anticholinergics; taken as 
needed
Y78 Y78
Short-acting 
anticholinergics
Ipratropium I–Iv Monotherapy or in combination with 
short-acting β-agonist; taken as needed
Y79 Y10,79 N10
Long-acting β-agonists Salmeterol
Formoterol
Arformoterol
II–Iv Monotherapy or in combination with 
anticholinergics
Y79,80 Y79 N80,81
Long-acting 
anticholinergics
Tiotropium II–Iv Monotherapy or in combination with 
β-agonist
Y82,83 Y82 N82
Inhaled glucocorticoids Fluticasone
Budesonide
III–Iv In combination with long-
acting β-agonist or anticholinergics
May be used in COPD stages I and II 
if patient is asthmatic
Y84–86 Y84 N81
Oxygen therapy Iv Supplemental therapy for patients with 
severe, chronic hypoxemia
Y85 Y85 Y86
Smoking cessation Behavioral therapy
Nicotine replacement 
therapy
Bupropion
varenicline
I–Iv Strongly recommended as a goal for all 
COPD patients who smoke, regardless 
of disease severity or progression
Y13 Y10,87 Y13
Influenza vaccination Trivalent inactivated 
vaccine
I–Iv Annual treatment to reduce incidence 
of viral infection and related symptom 
exacerbations
Y88
Pneumococcal vaccine 14-valent pneumococcal 
vaccine
23-valent pneumococcal 
vaccine 
I–Iv Given to reduce incidence of bacterial 
infection and related
symptom exacerbations
N89 N89
Abbreviations: Y, yes; N, no significant benefit.International Journal of COPD 2009:4 423
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cough and chronic phlegm production significantly improved 
in participants who received a smoking intervention 
(P  0.0001).12 Although less than one-quarter (21.7%) of 
study subjects in the smoking intervention group achieved 
smoking abstinence at the end of the 5-year study (com-
pared to 5.4% in usual care) all-cause mortality at 14½-year 
follow-up was significantly lower among participants who 
received a smoking intervention compared to those who did 
not (8.83 vs 10.38 deaths per 1,000 person-years; P = 0.03). 
Mortality due to non cancerous respiratory disease was 
significantly lower in the smoking intervention group than 
in usual care (0.56 vs 1.08 deaths per 1000 person-years, 
P = 0.01).13
The findings of the LHS highlight the critical role 
of smoking cessation in the slowing of COPD disease 
progression and provides empiric support for the idea 
that smoking cessation is “the most important therapeutic 
intervention in patients with COPD.”14 Pulmonary and 
thoracic societies universally consider smoking cessation 
a critical and indispensible component of COPD manage-
ment.15–18 Specifically, the GOLD Workshop has identified 
smoking cessation as the most significant strategy for COPD 
risk reduction and recommends that all smokers be offered 
smoking cessation interventions.4
Comprehensive treatment 
for tobacco dependence
The United States Public Health Service (USPHS) Clinical 
Practice Guideline Treating Tobacco Use and Dependence 
concluded that strong evidence supported the use of both 
behavioral and pharmacotherapeutic interventions for 
increasing tobacco abstinence rates. The USPHS recom-
mended the use of two types of behavioral counseling which 
have been consistently shown to increase smoking abstinence 
rates: (1) providing practical counseling such as problem-
solving, and skills training; (2) providing support during a 
smoker’s direct contact with a clinician.19
Tobacco dependence is best managed by treating it as 
a chronic disease: implementing systems to identify all 
people who smoke, providing brief treatment to all identified 
smokers, and arranging for more intensive interventions 
when needed.20,21 As with other chronic problems, relapse 
is the most likely outcome from any single treatment 
intervention. While some smokers may achieve long-term 
smoking abstinence (6 months) after a single attempt, 
many others will try to quit multiple times and repeatedly 
relapse.22,23 Re-engagement of patients in the quitting process 
is critical. Medication adjustments and behavioral support 
should be provided until long-term abstinence is achieved.
Frequent screening at follow-up visits and the offering of 
new medications can build confidence and reengage patients 
in treatment.
Identifying tobacco users
Establishing a systematic process to identify all tobacco 
users is critical. To increase the likelihood of addressing 
tobacco use, clinicians should have tobacco use status infor-
mation available before they walk in the examination room. 
Providing advice to quit smoking increases success, and 
patients who are advised to quit report higher satisfaction 
with clinical encounters. Although many patients are asked 
about smoking and advised to quit, few patients receive 
assistance or referral to quit.24
Starting the conversation
Communicating about smoking during a health care visit can 
be challenging for providers and difficult for patients. Most 
general practitioners acknowledge that counseling smokers to 
quit is important and can be effective. However, providers are 
frequently concerned that their interventions may negatively 
impact patient satisfaction despite evidence to the contrary.25 
In addition, providers may have a limited repertoire of 
counseling skills for addressing tobacco use with patients. 
Qualitative studies have found that there is a tendency by 
general practitioners to have discussions about stopping 
smoking only with patients who are motivated or to limit the 
discussions to health problems caused by smoking.26
Most smokers are ambivalent about stopping smoking 
despite knowing that smoking causes health problems. 
Many factors conflict with the desire to stop smoking. 
Patients anticipate the enjoyment from cigarettes that has 
been strongly paired with situations and stimuli that are 
present throughout their day-to-day activities. Withdrawal 
can be quite painful and relief from withdrawal can be very 
positively reinforcing. Patients may have concerns about loss 
of self esteem if a quit attempt fails, concerns about weight 
gain associated with quitting, and difficulty envisioning how 
they will manage to “fill the void” once they stop smoking.27 
The combination of limited counseling repertoire among 
providers and the multiple reasons underlying patient ambiva-
lence can decrease the likelihood that patients will talk with 
their providers about tobacco use and even inhibit patients’ 
reporting of tobacco related health symptoms.28 However, 
motivation to stop smoking can quickly change, and people 
who smoke can be helped to make a quit attempt despite 
being minimally motivated at first.29,30International Journal of COPD 2009:4 424
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Brief interventions adapted from Motivational Interviewing 
can help to engage a patient in a positive discussion about 
treatment options or prepare the patient to participate in more 
intensive treatment.31 One of the main barriers to engaging 
patients in an in-depth discussion of treatment options may 
be the difficulty in starting the conversation. A few simple 
questions can be effective for engaging identified smokers 
such as: (1) beginning with a non-judgmental open-ended 
question, (2) eliciting the patient’s self-perceived importance 
and confidence for stopping, and (3) assessing past quit 
attempts and treatment.32,33
A useful opening question is “What are your thoughts 
and feelings about stopping smoking?” This can assure 
the patient that the physician is interested in the patient’s 
perspective and provide useful information about a patient’s 
self-perceived obstacles to and benefits expected from 
quitting smoking. The motivation to stop smoking is a 
function of the self-assessed importance a patient places 
on quitting as well as their self-efficacy for succeeding. 
Scaling for importance and confidence can be used to elicit 
and strengthen a patient’s motivation to make a quit attempt 
and can be a function of the self-assessed importance placed 
upon quitting, and/or how successful the patient believes they 
will be if they try to quit. To assess both domains, providers 
can ask the following “scaling questions”: “On a scale of 
0 to 10, with 0 being not important at all, how important 
it is for you to stop smoking?” and “On a scale of 0 to 10, 
with 0 being not being not confident at all, how confident are 
you in your ability to stop smoking?” The provider can then 
follow-up by asking the patient to elaborate from his or her 
perspective on why it is important to quit, and share what 
makes them feel confident they can succeed. The provider 
can then join the patient to discuss options for enhancing 
confidence by building future success on past success. 
Deciding on a plan of therapy can be facilitated by asking 
“What has helped you in the past to stop smoking for even 
brief periods of time?” If a patient is willing to make a quit 
attempt, sufficient treatment intensity should be applied to 
maximize the likelihood of success.
Incorporating behavioral counseling
A dose-response relationship exists between counseling 
time and tobacco dependence treatment outcomes.34 Many 
hospitals, health departments and health care facilities 
have hired or trained tobacco treatment specialists (TTS). 
More allied health professionals are becoming certified as 
tobacco treatment specialists (attud.org),35 and standards 
for providing evidence-based treatment are becoming 
recognized. TTS provide assurance to the referring clinician 
that the tobacco use intervention is consistent with evidence-
based guidelines.
If a provider does not have local evidence-based tobacco 
treatment programs at his or her disposal, a telephone quitline 
can provide support. Each state in the United States, provinces 
in Canada, and jurisdictions in many other countries provide 
tobacco treatment counseling via the telephone. The simplest 
way for practitioners in the United States to engage patients 
in the tobacco quitline is to tell patients to call 1-800-
QUITNOW after leaving the office. Through the National 
Network of Tobacco Cessation Quitlines, callers will be 
routed to the tobacco quitline in their state. States have 
differing levels of support that they can provide, and patients 
can receive this information when they call. Practitioners can 
also learn about the state-specific service offerings through 
the National Quitline Consortium website (naquitline.org).36 
The Internet may also be effective in providing support to 
patients who are trying to quit smoking. A number of web 
sites have been developed to support quit attempts such as 
the American Legacy website “Become an Ex” (becomeanex.
org) and Quitnet (quitnet.com). The US National Cancer 
Institute publishes “Clearing the Air,” a comprehensive guide 
to quitting smoking that is designed specifically for patient 
use. Smokers can order a free print copy of the guide or view 
it online (smokefree.gov).
Pharmacotherapy
Seven “first-line” pharmacotherapies are currently available 
for facilitating smoking cessation: five nicotine replacement 
therapies (ie patch, gum, lozenge, inhaler and nasal spray), 
bupropion sustained-release (SR) and varenicline. Clonidine 
and nortriptyline have been identified as “second-line” 
medications.19 “First-line” medications should be selected 
initially because of their well-reported efficacies and 
favorable side effect profiles.
All of the available pharmacotherapies indicated for 
the treatment of smoking cessation have been shown to be 
effective as monotherapy and are often used as such for light 
smokers (10 cigarettes per day). Our general approach at the 
Mayo Nicotine Dependence Center for moderate and heavy 
smokers (10 cigarettes per day) is to prescribe the nicotine 
patch to provide continuous dosing and the ad libitum 
nicotine replacement products (ie nicotine gum, nicotine 
nasal spray, nicotine inhaler, nicotine lozenge) to cover 
sudden urges and cravings. As a rough guide, the required 
patch dose (in milligrams) should be the same or slightly 
more than the number of cigarettes per day (cpd) smoked. International Journal of COPD 2009:4 425
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For example, patients who smoke 30 cigarettes per day could 
be started on a nicotine patch dose of 35 mg/day (21 mg + 
14 mg patches). We offer bupropion SR concomitantly if 
there are no contraindications. While combination therapy 
with multiple nicotine replacement therapies is not an FDA-
approved treatment strategy, available evidence suggests that 
combination therapy increases smoking abstinence rates over 
monotherapy.37–40
Varenicline is appropriate for patients who have never 
tried any pharmacotherapy for smoking cessation and 
for those who have relapsed from abstinence using other 
medications. The recommended dosing for varenicline is 
0.5 mg once daily for three days, twice daily for four days, 
then 1 mg twice daily for 11 weeks. Starter packs for the 
first month of therapy with the “ramp-up” are available in 
some locations. Patients should plan to quit on day 8 (Target 
Quit Day) of therapy, the point at which the target dose of 
varenicline is reached. We continue varenicline for 3 months 
beyond the initial 3 months if patients are at a self-identified 
risk for relapse.41
Interventions for smokers  
with comorbid COPD
Tobacco use interventions in patients with COPD have 
been demonstrated to be effective for increasing smoking 
abstinence rates. The LHS demonstrated that a combination 
of behavioral counseling and nicotine replacement therapy 
(NRT) was effective for promoting smoking cessation in 
COPD patients. In an 11-year follow-up of the LHS, 21.9% 
of participants in the smoking intervention group achieved 
long-term smoking abstinence compared to 6.0% of 
participants in the control group (P = 0.001).11 Several other 
trials assessing the efficacy of pharmacotherapy for smoking 
cessation have been conducted in patients with COPD with 
mixed results. One study evaluated the efficacy of 12 weeks 
of bupropion SR for smoking cessation among 404 COPD 
patients. While bupropion SR increased smoking absti-
nence rates at 26 weeks compared to placebo (prolonged 
abstinence 16% vs 9%, P  0.05) no statistically significant 
difference in abstinence rates was observed between the 
two treatment groups at 12 months.42,43 In contrast, in a 
randomized trial of 370 patients with COPD randomized 
to NRT (sublingual tablet) or placebo, NRT significantly 
increased smoking abstinence rates at 12 months compared 
to placebo (biochemically confirmed 7-day point prevalence 
smoking abstinence: 17% vs 10%; odds ratio [OR]: 1.97; 
95% CI: 1.06 to 3.67).44 In a study evaluating the compara-
tive efficacy of bupropion SR and nortriptyline for smoking 
cessation, 255 subjects with COPD or at risk for COPD 
were randomized to bupropion SR (150 mg twice daily), 
nortriptyline (75 mg once daily) or placebo for 12 weeks. 
Among the subjects with COPD, 26-week prolonged 
smoking abstinence rates were highest in the bupropion 
group (27.3% vs 21.2% nortriptyline vs 8.3% placebo).45 
The only statistically significant difference in abstinence 
was between bupropion SR and placebo (P = 0.03).
Varenicline for smoking cessation
Varenicline is the newest addition to the armamentarium of 
pharmacotherapies for the treatment of tobacco dependence. 
Varenicline offers new hope to patients with COPD and other 
co-morbidities attempting to achieve tobacco abstinence.
Pharmacology of varenicline
The addictiveness of a drug is directly related to how rapidly 
it enters the central nervous system, and smoking a cigarette 
is the quickest way to deliver nicotine to the human body. 
The addictiveness of nicotine is comparable to heroin, 
cocaine, and alcohol.46 Nicotine “hijacks” neural networks 
to produce reward by affecting the release of the dopamine 
in the mesolimbic system of the brain. Systemically admin-
istered nicotine increases extracellular levels of dopamine in 
the nucleus accumbens47 by acting on nicotinic acetylcholine 
receptors (nAChRs).48
Neuronal nAChR receptors are ion channels comprised 
of α- and β-subunits.49 Six or more of these subunits (α3, α4, 
α5, α6, β2, and β3) are expressed in the dopaminergic neurons 
of the midbrain. The α4β2 nAChR in the mesolimbic system 
plays a critical role in the reinforcing power of nicotine.
Varenicline is an oral medication synthesized from the 
plant alkaloid cytisine which is known to bind predominantly 
and with high affinity to cerebral α4β2 nAChRs.50 Binding 
at the α4β2 nAChRs as a partial agonist,51,52 varenicline 
stimulates the release of dopamine, which mediates the 
“reward” reinforcing cigarette smoking while simultaneously 
blocking the binding of nicotine obtained from tobacco. As a 
result of this activity, nicotine withdrawal symptoms and 
cravings are suppressed and reduced pharmacologic reward 
is experienced if a tobacco-dependent patient smokes a 
cigarette while taking varenicline.
Efficacy of varenicline
Several randomized, placebo-controlled clinical trials have 
demonstrated the efficacy of varenicline for increasing 
tobacco abstinence rates among cigarette smokers.41,53–59 Two 
identically designed clinical trials53,54 compared varenicline International Journal of COPD 2009:4 426
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1 mg twice per day with bupropion SR 150 mg twice per day 
and placebo. At end-of-treatment (12 weeks), the 7-day point 
prevalence smoking abstinence rates in both studies were 
21% with placebo, 36% with bupropion SR and 50% with 
varenicline; all pair-wise comparisons within each study were 
statistically significant (P  0.001). After 1 year (9 months 
after treatment had stopped), point prevalence smoking 
abstinence rates were 28%53 and 31%54 for varenicline 
and statistically different from placebo (P  0.001 for both 
studies). Consistent with the proposed mechanism of action, 
varenicline decreased the urge to smoke, negative affect, and 
restlessness.53,54
Varenicline also appears to be superior to NRT. In a study 
of 412 patients, short-term cessation rates (4 weeks after 
target quit date) were observed to be higher with varenicline 
than with NRT (adjusted OR 1.70; 95% CI: 1.09 to 2.67).60 
In an open-label study of patients randomized to 12 weeks of 
varenicline or 10 weeks of the 21 mg/day nicotine patch with 
tapering, the biochemically confirmed continuous abstinence 
rates (last 4 weeks of treatment) among 746 subjects eligible 
for analysis were significantly greater with varenicline 
compared to the nicotine patch (55.9% vs 43.2%; OR 1.70; 
95% CI: 1.26 to 2.28).61 Furthermore, varenicline signifi-
cantly reduced craving, withdrawal, and smoking satisfaction 
compared to nicotine patch. A systematic review concluded 
that the pooled relative risk (RR) for continuous smoking 
abstinence at 1 year for varenicline compared to NRT is 
1.31 (95% CI: 1.01 to 1.71).62
In a study investigating the efficacy of an additional 
12 weeks of varenicline, point prevalence smoking 
abstinence rates were higher in the intervention group 
(6 months of varenicline) compared to control (3 months 
varenicline + 3 months placebo) at week 24 (OR 2.82; 95% 
CI: 2.18 to 3.64) and week 52 (OR 1.33; 95% CI: 1.06 to 
1.67).41 In a study investigating the long-term (52 weeks) 
safety of varenicline, the 7-day point prevalence smoking 
abstinence rate was 36.7% in the varenicline group and 7.9% 
in placebo. A single serious adverse event in the varenicline-
treated group (ie subcapsular cataracts) was observed.55
Tolerability and safety of varenicline
The most frequently reported adverse effects of varenicline 
are nausea (29.4% vs 10% placebo), insomnia (14.3% vs 
12.4%), abnormal dreams (13.1% vs 3.5%), headache 
(12.8% vs 12.6%), and constipation (9% vs 1.5%).54 
Nausea is generally mild (72%) to moderate (23%) in 
intensity, becomes less severe with continued drug use, 
and causes 2.3% of patients to discontinue treatment. 
Taking the medication with food can minimize nausea 
without decreasing the drug’s bioavailability.
Within 2 years of the drug’s approval, the United States 
Food and Drug Administration (FDA) received reports of 
agitation, changes in behavior, depressed mood, suicidal 
ideation, and attempted and completed suicide associated with 
varenicline use. These symptoms have started days to weeks 
after initiating therapy and during withdrawal of therapy. 
In light of these findings, the FDA issued a public health 
advisory63 for varenicline and advised health care providers 
to monitor patients for behavior and mood changes.
Varenicline in smokers 
with medical comorbidity
COPD
A randomized, double-blind, placebo-controlled multicenter 
study of varenicline administered for 12 weeks with 
follow-up through 52 weeks was initiated in 500 subjects 
with spirometrically confirmed mild to moderate COPD. The 
study was recently completed; however, the results have not 
yet been published (clinicaltrials.gov registration number 
NCT00285012).64
Cardiovascular disease
The effect of smoking on the development and progression 
of coronary heart disease (CHD) is well known, and the 
benefit of quitting is profound.65,66 The Surgeon General 
of the United States has named cigarette smoking as the 
chief preventable cause of CHD and attributed one third 
of all CHD-related mortalities to smoking, noting that the 
CHD-related death rate is 70% greater in smokers than in 
nonsmokers.67,68 In a cohort study on 7735 British, middle-
aged men,69 the age-adjusted relative risk for sudden cardiac 
death (SCD) was related to smoking status. Compared to 
never smokers, the relative risk for SCD was significantly 
higher in male current smokers (RR: 2.3; 95% CI: 1.2 to 4.0) 
and slightly higher among former smokers (RR: 1.4; 95% 
CI: 0.8 to 2.9).
A high degree of co-morbidity exists between cardio-
vascular disease (CVD; CVD includes stroke and CHD) 
and COPD. A population-based study of 20,296 individuals 
observed that, adjusting for age, sex, smoking, body mass 
index, race and education, individuals with severe and very 
severe COPD have an increased risk of CVD (OR 2.4; 
95% CI: 1.9 to 3.0).70 Among participants who continued 
to smoke through the 14.5 year follow-up of the LHS, 
CVD was the second most common cause of death, and International Journal of COPD 2009:4 427
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lung cancer was the leading cause.13 An estimated 20% of 
COPD patients 65 years of age have undiagnosed comorbid 
heart failure.71
Varenicline appears to be safe and effective for smokers 
with CHD who wish to quit. The first reported trial of 
varenicline use in patients with CHD was a multicenter study 
involving 703 participants aged 35 to 75 years randomized to 
varenicline (1 mg twice daily) or placebo for twelve weeks 
along with behavioral support. At 52 weeks, biochemically 
confirmed prolonged abstinence (4 week grace period) was 
19.8% for varenicline and 7.4% for placebo (OR: 3.19; 95% 
CI: 1.97 to 5.18). The most common adverse events related 
to the study drug were nausea (29.5%), headache (12.7%) 
and insomnia (11.9%). Only 2.3% of varenicline-treated 
subjects discontinued the study medication as compared to 
1.4% of subjects in the placebo group. The efficacy reported 
in this study was similar to previous trials of varenicline 
for smoking cessation in a general population of cigarette 
smokers (21.9% vs 8.4%53 and 23.0% vs 10.3%).54 No studies 
directly comparing the efficacy of varenicline with other 
pharmacotherapies for smoking cessation in patients with 
CVD have been reported.
Varenicline in smokers 
with psychiatric comorbidity
Because of a higher prevalence of cigarette smoking and a 
lower likelihood of quitting among individuals with psychi-
atric illness, these patients are at high risk for developing 
smoking-related disease.72 Unfortunately, patients with 
mental illness are often not included in trials investigating 
pharmacotherapeutic smoking interventions.53–57
However, the safety and efficacy of varenicline has 
been evaluated in some studies that included patients 
with psychiatric illnesses. Within an open-label study on 
a group of 412 smokers receiving treatment at a tobacco 
dependence clinic, 111 participants had been diagnosed 
with psychiatric illnesses. When data from all study partici-
pants were pooled, the biochemically confirmed smoking 
abstinence rates four weeks after the target quit date were 
higher among patients receiving varenicline than those 
receiving NRT (72.1% vs 61.3%; adjusted OR: 1.70; 95% 
CI: 1.09 to 2.67). Varenicline was equally efficacious 
and not associated with a higher incidence or severity of 
adverse drug reactions among patients with psychiatric 
comorbidity. No cases of exacerbations of mental illness were 
reported.60 A comparative study on patients with and without 
a history of depression came to a similar conclusion about 
the efficacy and safety of the drug in depressed patients.73
Product label warning
Since the original FDA advisory on psychiatric health 
concerns related to the use of varenicline was issued in 
2008,63 more reports of psychiatric events possibly related 
to varenicline have been reported.74,75 In response to these 
mounting reports, the FDA called on Pfizer, the manufac-
turer of varenicline (branded in the US as Chantix®) to more 
prominently emphasize concerns about adverse psychiatric 
potentially associated with the drug.76 Accordingly, Pfizer 
sent letters to health care professionals and updated warnings 
on both patient information sheets and company websites.77 
The new Chantix® product label warning stresses that health 
care professionals should monitor patients for possible 
varenicline-induced psychiatric events and encourages 
patients to discontinue the drug and contact a physician if 
they experience an adverse psychiatric event.77
In a press release by the FDA, Janet Woodcock, director 
of the agency’s Center for Drug Evaluation and Research, 
emphasized the need to weigh the risk of adverse events 
against the benefits of smoking cessation with varenicline.76 
Because the exact relationship between adverse psychiatric 
events and varenicline is unclear, the FDA concluded that 
Pfizer will have to conduct a trial to assess the prevalence 
of psychiatric adverse events in patients taking the drug.76
Conclusions
Given the health risks associated with smoking and the relation-
ship between smoking status and the progression of COPD and 
the incidence of CHD, all patients with COPD and CHD who 
smoke should be offered a comprehensive smoking cessation 
intervention. Patients with psychiatric illnesses have a higher 
prevalence of smoking and may have a difficult time quitting. 
The most effective pharmacologic intervention available is var-
enicline; however, prescribers should closely monitor patients 
due to the possibility that the drug may cause psychiatric insta-
bility. Behavioral intervention should also be incorporated into 
every patient’s treatment plan. When face-to-face counseling is 
not available or feasible, telephone quit lines and self-help guides 
can offer support for smokers as they make a quit attempt.
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